title: Current status and future prospects for anti-angiogenic therapies in cancer.
abstract: BACKGROUND
  Angiogenesis is essential for tumour growth and development and since the pioneering work of Judah Folkman several anti-angiogenic strategies have now been successfully employed.
  
  
  OBJECTIVE
  This article aims to present a detailed review of current knowledge of the main pathways involved in angiogenesis, the strategies employed for inhibition and the current status of angiogenesis inhibitors in therapeutic use.
  
  
  METHODS
  A systematic review of the literature was undertaken including angiogenesis in cancer and angiogenesis inhibitors in pre-clinical and clinical trials.
  
  
  CONCLUSIONS
  While angiogenic inhibitors are now in clinical use, their limited benefits mean we must urgently develop strategies to improve the efficacy of this approach.
authors.affiliation: University of Sheffield, School of Medicine and Biomedical Sciences, Microcirculation Research Group, Academic Unit of Surgical Oncology, Beech Hill Road, Sheffield, South Yorkshire, S10 2RX, UK +44 (0)114 226 5852 ; +44 (0)114 271 3314 ; c.a.staton@sheffield.ac.uk.
authors.forename: Carolyn A
authors.initials: CA
authors.lastname: Staton
authors.forename: Nicola J
authors.initials: NJ
authors.lastname: Brown
authors.forename: Malcolm Wr
authors.initials: MW
authors.lastname: Reed